文献速递甲状腺疾病

安罗替尼新辅助治疗局部晚期甲状腺癌:单臂II期临床试验

The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
PubMed 文献 · Thyroid · 2021-11-29

本研究为单臂II期临床试验,评估安罗替尼(12 mg口服,用2周停1周,2-6周期)新辅助治疗局部晚期甲状腺癌的疗效与安全性。共入组13例,客观缓解率76.9%(95%CI 46.2-95.0%),意向治疗人群R0/R1切除率61.5%,符合方案人群72.7%。常见不良事件为高血压(76.9%)、高甘油三酯血症(69.2%)等,多为1-2级。

要点

  • 安罗替尼新辅助治疗局部晚期甲状腺癌客观缓解率达76.9%。
  • 意向治疗人群R0/R1切除率61.5%,符合方案人群72.7%。
  • 不良事件与安罗替尼已知安全性一致,多为1-2级。

核心结论

  • 安罗替尼新辅助治疗局部晚期甲状腺癌显示抗肿瘤活性,多数患者实现R0/R1切除。

研究设计与样本

  • 单臂II期临床试验,入组13例局部晚期甲状腺癌患者,接受安罗替尼12 mg口服每日一次,用2周停1周,2-6周期。

主要发现

  • 客观缓解率为76.9%(95%CI 46.2-95.0%)。
  • 意向治疗人群R0/R1切除率为61.5%,符合方案人群为72.7%。
  • 中位缓解时间为61.5天,18周疾病控制率为92.3%。
  • 无患者接受输血或气管切开。
  • 常见不良事件包括高血压(76.9%)、高甘油三酯血症(69.2%)、蛋白尿(53.8%)、促甲状腺激素升高(53.8%)、胆固醇升高(53.8%)和手足综合征(38.5%)。

关键数值与推荐

  • 入组标准包括年龄14-80岁、局部晚期甲状腺癌可从手术获益、至少一个可测量病灶。

临床怎么用

  • 安罗替尼新辅助治疗可作为局部晚期甲状腺癌患者的新选择,以提高R0/R1切除机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Surgery is the primary treatment for locally advanced thyroid cancer. For some cases, R0/R1 resection could not be achieved at initial diagnosis and neoadjuvant treatment would be an option. Anlotinib is a multitarget tyrosine kinase inhibitor, which demonstrated antitumor activity in radioiodine-refractory differentiated thyroid cancer and medullary thyroid cancer. We aimed to evaluate the efficacy and safety of anlotinib in locally advanced thyroid cancer in the neoadjuvant setting. Methods: This single-arm phase II study investigated the efficacy and safety of anlotinib (12 mg orally daily, 2 weeks on/1 week off) for 2-6 cycles in patients with locally advanced thyroid cancer in the neoadjuvant setting. The key eligibility criteria included age 14-80 years old; locally advanced thyroid cancer that would benefit from surgery, and at least one measurable lesion. Operable patients received surgery after neoadjuvant treatment. The primary endpoint was objective response rate (ORR). Results: A total of 13 patients were enrolled and received an average of 3.5 cycles of anlotinib treatment. The ORR of anlotinib was 76.9% (95% confidence interval: 46.2-95.0%). The R0/R1 resection rate in the intent-to-treat population was 61.5% and in the per-protocol population was 72.7%. The median time to response was 61.5 days, and the disease control rate at 18 weeks was 92.3%. No patients had blood transfusion or tracheotomy. Most adverse events (AEs) were grade 1 or 2 and tended to discontinue when neoadjuvant treatment ceased. Common AEs of all grades were hypertension (76.9%), hypertriglyceridemia (69.2%), proteinuria (53.8%), thyrotropin increase (53.8%), cholesterol elevation (53.8%), and hand-foot syndrome (38.5%). Conclusions: Anlotinib demonstrated antitumor activity in the neoadjuvant treatment and the majority of patients achieved R0/R1 resection. AEs were consistent with the known anlotinib AE profile. These results suggest that anlotinib neoadjuvant treatment represents a new option for locally advanced thyroid cancer. Clinical Trial Registration Number: NCT04309136.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Huang NS, Wei WJ, Xiang J, et al. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial. Thyroid. 2021. PMID: 34610756. doi:10.1089/thy.2021.0307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。